Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | TAS2R8 | Q9NYW2 | 7/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599462 | 0.91 | LPL (0.46) | MEN1KMT2AFFAR1TAS2R8LPL | |
| SCHEMBL21049901 | 0.86 | MEN1 (0.44) | MEN1KMT2AFFAR1TAS2R8LPL | |
| SCHEMBL21089621 | 0.85 | MEN1 (0.46) | MEN1KMT2AFFAR1TAS2R8LPL | |
| SCHEMBL29801489 | 0.85 | DGAT1 (0.52) | MEN1KMT2AFFAR1ALDH1A1DGAT1 | |
| SCHEMBL14858471 | 0.85 | DGAT1 (0.52) | MEN1KMT2AFFAR1ALDH1A1DGAT1 | |
| SCHEMBL14858045 | 0.85 | MEN1 (0.60) | MEN1KMT2AFFAR1TAS2R8ALDH1A1 | |
| SCHEMBL29801659 | 0.85 | MEN1 (0.60) | MEN1KMT2AFFAR1TAS2R8ALDH1A1 | |
| SCHEMBL16968989 | 0.81 | FFAR1 (0.46) | MEN1KMT2AFFAR1KLKB1 | |
| SCHEMBL21049914 | 0.81 | FFAR1 (0.41) | MEN1KMT2AFFAR1TAS2R8LIPG | |
| SCHEMBL21049930 | 0.80 | MEN1 (0.45) | MEN1KMT2AFFAR1TAS2R8LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689661-B | Macrocyclic inhibitors of myeloperoxidase | 百时美施贵宝公司 | 2021-10-15 | — | — | CN | disclosed |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MEN1 4596/4885KMT2A 3392/4885FFAR1 2438/4885 |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MEN1 4596/4885KMT2A 3392/4885FFAR1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.